Record number:
256
Adverse Occurrence type:
MPHO Type:
Estimated frequency:
Most recent risk assessment for leukemia, lymphoma and plasmacytoma (Council of Europe, 2022):
Leukaemia, lymphoma and plasmacytoma diagnosed during donor procurement: These cancers are classified as an unacceptable risk for organ donation. Leukaemia, lymphoma and plasmacytoma in the donor history: Active (acute or chronic) leukaemia, lymphoma and plasmacytoma are an unacceptable risk for organ donation. Treated acute leukaemia and lymphoma after a definite disease-free interval of 10 years may be considered for organ donation with an assumed high risk for transmission.
Time to detection:
7 years
Alerting signals, symptoms, evidence of occurrence:
The diagnosis of multiple myeloma was unequivocal and based on positive results from serum electrophoresis (IgA spike), skeletal survey and bone marrow investigations.
Demonstration of imputability or root cause:
Certain. The donor origin of the myeloma cells was confirmed by DNA fingerprinting
Imputability grade:
3 Definite/Certain/Proven
Groups audience:
Suggest new keywords:
Case report
Deceased donor
Kidney transplant
Multiple myeloma/plasmacytoma leukemia
Suggest references:
aaa
Expert comments for publication:
In light of the 7 year interval between transplant and neoplasia in the recipient, most would apply the term "donor-derived" in lieu of "donor-transmitted",to reflect the (unproven) likelihood that this represents a post-transplant malignant transformation and not a fully developed tumor that was transmitted at the time of transplant.